皮米因通过调节肠道微生物群和减轻炎症和氧化应激来缓解DSS诱导的大肠炎
Xuke Guan1,2, Deping Han1, Haojie Sha1
1Shandong Laboratory of Advanced Agricultural Sciences in Weifang, Peking University Institute of Advanced Agricultural Sciences, Weifang 261325, China.
International journal of molecular sciences
|November 27, 2025
概括
皮米因 (PM) 是一种来自大的化合物,通过向炎症和氧化应激,有效治疗性结肠炎 (UC). 它通过调节微生物群和增强有益的短链脂肪酸 (SCFA) 来恢复肠道健康.
科学领域:
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
- 微生物学 微生物学
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性肠病,治疗选择有限.
- 炎症,氧化应激和肠道失调是UC病变的关键因素.
- 年龄大衍生的类固醇类化合物,Peimine (PM),显示潜在的治疗益处.
研究的目的:
- 调查Peimine (PM) 对性结肠炎 (UC) 的多目标治疗机制.
- 为了验证PM在DSS诱导的UC的体内小鼠模型中的有效性.
- 探索PM对炎症信号通路,氧化应激,肠道微生物群和短链脂肪酸 (SCFA) 生产的影响.
主要方法:
- 网络药理学被用来确定PM的潜在目标和途径.
- 为了在体内验证,建立了硫酸 (DSS) 诱导的UC的小鼠模型.
- 评估了疾病活动指数,结肠长度,上皮屏障完整性,细胞因子水平 (TNF-α,IL-6),氧化应激标志物,肠道微生物群组成和便SCFA水平.
主要成果:
- 服用PM显著减轻了DSS诱导的UC严重程度,减少了疾病活动并恢复了结肠的长度.
- 细分泌物治疗降低了促炎性细胞因子 (TNF-α,IL-6) 和氧化损伤.
- 微粒素改变了肠道微生物群的形状,有利于有益的细菌 (Akkermansia muciniphila, Lactobacillus spp.) 并挽救了便中的SCFA生产,将微生物变化与粘膜愈合联系起来.
结论:
- 皮米因 (PM) 通过同时抑制PI3K-AKT,JAK-STAT和HIF-1信号通路,表现出强大的抗结肠炎作用.
- 聚氨酸通过准炎症,氧化还原平衡和肠道微生物群之间的交叉声调来证明其治疗潜力.
- 粉代表了一种有前途的天然化合物,通过多目标药理策略来管理性结肠炎.
相关概念视频
Drugs for Treatment of Diarrhea-Predominant IBS
604
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
604
Drugs for Treatment of Ulcerative Colitis in IBD
435
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
435
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
620
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
620
Drugs for Treatment of Constipation-Predominant IBS
682
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
682
Inflammatory Bowel Disease IV: Pharmacological Management
452
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
452


